CIK 0001088856 · Large accelerated filer
CORCEPT THERAPEUTICS INC
Sign in to watch- Ticker
- CORT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770487658
- Phone
- 650.688.8803
- Business address
- 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,067,988
- in 15 filings, $36.6M under 10b5-1 plans
Net −$41,067,988. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-03 | Mokari Atabak Chief Financial Officer | Shares withheld for taxes | −228 | $60.58 | $14K | 12,570 |
| 2025-03-03 | Mokari Atabak Chief Financial Officer | Grant or award | +232 | $59.07 | $14K | 12,802 |
| 2025-03-03 | Mokari Atabak Chief Financial Officer | Grant or award | +232 | 13,034 | ||
| 2025-03-03 | Robb Gary Charles Chief Business Officer | Shares withheld for taxes | −250 | $60.58 | $15K | 22,906 |
| 2025-03-03 | Robb Gary Charles Chief Business Officer | Grant or award | +292 | $59.07 | $17K | 23,198 |
| 2025-03-03 | Robb Gary Charles Chief Business Officer | Grant or award | +292 | 23,490 | ||
| 2025-02-28 | Maduck Sean See Remarks | Grant or award · Stock option (right to buy) 10b5-1 | +140,000 | 140,000 | ||
| 2025-02-28 | Lyon Joseph Douglas See Remarks | Grant or award · Stock option (right to buy) 10b5-1 | +140,000 | 140,000 | ||
| 2025-02-28 | Guyer William Chief Development Officer | Grant or award · Stock option (right to buy) 10b5-1 | +140,000 | 140,000 | ||
| 2025-02-28 | BELANOFF JOSEPH K Chief Executive Officer | Grant or award · Stock option (right to buy) 10b5-1 | +350,000 | 350,000 | ||
| 2025-02-28 | Hunt Hazel Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +140,000 | 140,000 | ||
| 2025-02-28 | Mokari Atabak Chief Financial Officer | Grant or award · Stock option (right to buy) | +140,000 | 140,000 | ||
| 2025-02-28 | Robb Gary Charles Chief Business Officer | Grant or award · Stock option (right to buy) | +140,000 | 140,000 | ||
| 2025-02-11 | Hunt Hazel Chief Scientific Officer | Option exercise | +150,000 | $3.29 | $494K | 268,581 |
| 2025-02-11 | Hunt Hazel Chief Scientific Officer | Shares withheld for taxes | −85,176 | $68.11 | $5.8M | 183,405 |
| 2025-02-11 | Hunt Hazel Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −150,000 | 0 | ||
| 2025-02-10 | Swisher Daniel N JR Director | Option exercise 10b5-1 | +2,200 | $12.13 | $27K | 2,200 |
| 2025-02-10 | Swisher Daniel N JR Director | Sale 10b5-1 | −2,200 | $68.08 | $150K | 0 |
| 2025-02-10 | Swisher Daniel N JR Director | Option exercise · Stock option (right to buy) 10b5-1 | −2,200 | 6,200 | ||
| 2025-02-03 | Maduck Sean See Remarks | Option exercise 10b5-1 | +11,986 | $3.88 | $47K | 97,304 |
Page 31 of 61 · 1,220 trades